UK AMD/DR EMR REPORT IX : comparative effectiveness of predominantly as needed (PRN) ranibizumab versus continuous aflibercept in UK clinical practice
© Article author(s) (or their employer(s) unless otherwise stated in the text of the article) 2017. All rights reserved. No commercial use is permitted unless otherwise expressly granted..
AIMS: To compare the effectiveness of continuous aflibercept versus pro re nata (PRN) ranibizumab therapy for neovascular age-related macular degeneration (nAMD).
METHODS: Multicentre, national electronic medical record (EMR) study on treatment naive nAMD eyes undergoing PRN ranibizumab or continuous (fixed or treat and extend (F/TE)) aflibercept from 21 UK hospitals. Anonymised data were extracted, and eyes were matched on age, gender, starting visual acuity (VA) and year of starting treatment. Primary outcome was change in vision at 1 year.
RESULTS: 1884 eyes (942 eyes in each group) were included. At year 1, patients on PRN ranibizumab gained 1.6 ETDRS (Early Treatment Diabetic Retinopathy Study) letters (95% CI 0.5 to 2.7, p=0.004), while patients on F/TE aflibercept gained 6.1 letters (95% CI 5.1 to 7.1, p=2.2e-16). Change in vision at 1 year of the F/TE aflibercept group was 4.1 letters higher (95% CI 2.5 to 5.8, p=1.3e-06) compared with the PRN ranibizumab group after adjusting for age, starting VA, gender and year of starting therapy. The F/TE aflibercept group had significantly more injections compared with the PRN ranibizumab group (7.0 vs 5.8, p<2.2e-16), but required less clinic visits than the PRN ranibizumab group (10.8 vs 9.0, p<2.2e-16). Cost-effectiveness analysis showed an incremental cost-effectiveness ratio of 58 047.14 GBP/quality-adjusted life year for continuous aflibercept over PRN ranibizumab.
CONCLUSION: Aflibercept achieved greater VA gains at 1 year than ranibizumab. The observed VA differences are small and likely to be related to more frequent treatment with aflibercept, suggesting that ranibizumab should also be delivered by F/TE posology.
| Medienart: |
E-Artikel |
|---|
| Erscheinungsjahr: |
2017 |
|---|---|
| Erschienen: |
2017 |
| Enthalten in: |
Zur Gesamtaufnahme - volume:101 |
|---|---|
| Enthalten in: |
The British journal of ophthalmology - 101(2017), 12 vom: 06. Dez., Seite 1683-1688 |
| Sprache: |
Englisch |
|---|
| Beteiligte Personen: |
Lee, Aaron Y [VerfasserIn] |
|---|
| Links: |
|---|
| Anmerkungen: |
Date Completed 04.12.2017 Date Revised 18.03.2022 published: Print-Electronic Citation Status MEDLINE |
|---|
| doi: |
10.1136/bjophthalmol-2016-309818 |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
NLM271637633 |
|---|
| LEADER | 01000naa a22002652 4500 | ||
|---|---|---|---|
| 001 | NLM271637633 | ||
| 003 | DE-627 | ||
| 005 | 20231224233134.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 231224s2017 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.1136/bjophthalmol-2016-309818 |2 doi | |
| 028 | 5 | 2 | |a pubmed24n0905.xml |
| 035 | |a (DE-627)NLM271637633 | ||
| 035 | |a (NLM)28478396 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 100 | 1 | |a Lee, Aaron Y |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a UK AMD/DR EMR REPORT IX |b comparative effectiveness of predominantly as needed (PRN) ranibizumab versus continuous aflibercept in UK clinical practice |
| 264 | 1 | |c 2017 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a ƒaComputermedien |b c |2 rdamedia | ||
| 338 | |a ƒa Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Date Completed 04.12.2017 | ||
| 500 | |a Date Revised 18.03.2022 | ||
| 500 | |a published: Print-Electronic | ||
| 500 | |a Citation Status MEDLINE | ||
| 520 | |a © Article author(s) (or their employer(s) unless otherwise stated in the text of the article) 2017. All rights reserved. No commercial use is permitted unless otherwise expressly granted. | ||
| 520 | |a AIMS: To compare the effectiveness of continuous aflibercept versus pro re nata (PRN) ranibizumab therapy for neovascular age-related macular degeneration (nAMD) | ||
| 520 | |a METHODS: Multicentre, national electronic medical record (EMR) study on treatment naive nAMD eyes undergoing PRN ranibizumab or continuous (fixed or treat and extend (F/TE)) aflibercept from 21 UK hospitals. Anonymised data were extracted, and eyes were matched on age, gender, starting visual acuity (VA) and year of starting treatment. Primary outcome was change in vision at 1 year | ||
| 520 | |a RESULTS: 1884 eyes (942 eyes in each group) were included. At year 1, patients on PRN ranibizumab gained 1.6 ETDRS (Early Treatment Diabetic Retinopathy Study) letters (95% CI 0.5 to 2.7, p=0.004), while patients on F/TE aflibercept gained 6.1 letters (95% CI 5.1 to 7.1, p=2.2e-16). Change in vision at 1 year of the F/TE aflibercept group was 4.1 letters higher (95% CI 2.5 to 5.8, p=1.3e-06) compared with the PRN ranibizumab group after adjusting for age, starting VA, gender and year of starting therapy. The F/TE aflibercept group had significantly more injections compared with the PRN ranibizumab group (7.0 vs 5.8, p<2.2e-16), but required less clinic visits than the PRN ranibizumab group (10.8 vs 9.0, p<2.2e-16). Cost-effectiveness analysis showed an incremental cost-effectiveness ratio of 58 047.14 GBP/quality-adjusted life year for continuous aflibercept over PRN ranibizumab | ||
| 520 | |a CONCLUSION: Aflibercept achieved greater VA gains at 1 year than ranibizumab. The observed VA differences are small and likely to be related to more frequent treatment with aflibercept, suggesting that ranibizumab should also be delivered by F/TE posology | ||
| 650 | 4 | |a Comparative Study | |
| 650 | 4 | |a Journal Article | |
| 650 | 4 | |a Multicenter Study | |
| 650 | 4 | |a Research Support, N.I.H., Extramural | |
| 650 | 4 | |a Research Support, Non-U.S. Gov't | |
| 650 | 4 | |a Age related macular degeneration | |
| 650 | 4 | |a aflibercept | |
| 650 | 4 | |a anti-VEGF therapy | |
| 650 | 4 | |a ranibizumab | |
| 650 | 7 | |a Angiogenesis Inhibitors |2 NLM | |
| 650 | 7 | |a Recombinant Fusion Proteins |2 NLM | |
| 650 | 7 | |a aflibercept |2 NLM | |
| 650 | 7 | |a 15C2VL427D |2 NLM | |
| 650 | 7 | |a Receptors, Vascular Endothelial Growth Factor |2 NLM | |
| 650 | 7 | |a EC 2.7.10.1 |2 NLM | |
| 650 | 7 | |a Ranibizumab |2 NLM | |
| 650 | 7 | |a ZL1R02VT79 |2 NLM | |
| 700 | 1 | |a Lee, Cecilia S |e verfasserin |4 aut | |
| 700 | 1 | |a Egan, Catherine A |e verfasserin |4 aut | |
| 700 | 1 | |a Bailey, Clare |e verfasserin |4 aut | |
| 700 | 1 | |a Johnston, Robert L |e verfasserin |4 aut | |
| 700 | 1 | |a Natha, Salim |e verfasserin |4 aut | |
| 700 | 1 | |a Hamilton, Robin |e verfasserin |4 aut | |
| 700 | 1 | |a Khan, Rehna |e verfasserin |4 aut | |
| 700 | 1 | |a Al-Husainy, Sahar |e verfasserin |4 aut | |
| 700 | 1 | |a Brand, Christopher |e verfasserin |4 aut | |
| 700 | 1 | |a Akerele, Toks |e verfasserin |4 aut | |
| 700 | 1 | |a Mckibbin, Martin |e verfasserin |4 aut | |
| 700 | 1 | |a Downey, Louise |e verfasserin |4 aut | |
| 700 | 1 | |a Tufail, Adnan |e verfasserin |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t The British journal of ophthalmology |d 1917 |g 101(2017), 12 vom: 06. Dez., Seite 1683-1688 |w (DE-627)NLM000087556 |x 1468-2079 |7 nnns |
| 773 | 1 | 8 | |g volume:101 |g year:2017 |g number:12 |g day:06 |g month:12 |g pages:1683-1688 |
| 856 | 4 | 0 | |u http://dx.doi.org/10.1136/bjophthalmol-2016-309818 |3 Volltext |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a GBV_NLM | ||
| 951 | |a AR | ||
| 952 | |d 101 |j 2017 |e 12 |b 06 |c 12 |h 1683-1688 | ||